Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$940K Sell
39,055
-713
-2% -$18.7K 0.02% 279
2026
Q1
$1.12M Buy
39,768
+2,231
+6% +$59.4K 0.02% 224
2025
Q4
$935K Sell
37,537
-663
-2% -$16.7K 0.02% 240
2025
Q3
$973K Buy
38,200
+2,117
+6% +$52.3K 0.02% 249
2025
Q2
$880K Buy
36,083
+6,571
+22% +$153K 0.02% 246
2025
Q1
$748K Sell
29,512
-9,309
-24% -$244K 0.02% 241
2024
Q4
$1.03M Sell
38,821
-5,136
-12% -$139K 0.02% 217
2024
Q3
$1.27M Buy
43,957
+2,386
+6% +$69.6K 0.03% 195
2024
Q2
$1.16M Sell
41,571
-12,988
-24% -$358K 0.03% 200
2024
Q1
$1.51M Buy
54,559
+7,609
+16% +$211K 0.04% 166
2023
Q4
$1.35M Buy
+46,950
New +$1.42M 0.04% 164

Other funds holding PFE

AlTi Global's PFE Position: Q2 2026 in Review

AlTi Global reduced its Pfizer (PFE) stake by 1.8% in Q2 2026, selling an estimated $18.7K and leaving 39,055 shares worth $940K. The position accounts for 0.02% of the portfolio, ranked #279.

AlTi Global first reported a position in PFE in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.51M in Q1 2024. 1,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • AlTi Global held 39,055 shares of Pfizer worth $940K as of Q2 2026.
  • AlTi Global sold 713 Pfizer shares in Q2 2026, an estimated $18.7K.
  • Pfizer made up 0.02% of AlTi Global's portfolio in Q2 2026, its #279 holding.
  • AlTi Global first reported a position in Pfizer in Q4 2023 and has held it in 11 quarters since.
  • AlTi Global's Pfizer position peaked at $1.51M in Q1 2024.
  • 1,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on AlTi Global's 13F filing for Q2 2026, filed 5 Aug 2026.